Top
Topic: The Interplay between Direct-Acting Antivirals and Hepatocellular Carcinoma in Chronic Hepatitis C

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 30 Nov 2019

Guest Editor(s)

  • Ming-Lung Yu, MD, PhD
    Professor, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University, Kaohsiung, Taiwan.

    Website | E-mail

Special Issue Introduction

Chronic hepatitis C (CHC) infection is one of the major etiologies of hepatocellular carcinoma (HCC). As with the observations in the interferon era, treating patients with directly acting antivirals significantly reduces HCC risk. However, the risk ratio reduction may be more limited in patients who already possess decompensated liver cirrhosis. In terms of HCC recurrence, it has been suggested that HCC may recur more frequently and aggressively after DAA intervention. The difficulty in performing a prospective study comparing to non-treatment cohort may render inconclusive results. The issue of washout period between curative HCC treatment and initiating DAA treatment may also determine the interpreting of the outcomes. With more evidence emerging, the HCV eradication by DAA should not have a negative impact on HCC recurrence.
From another perspective, whether the presence of active HCC would compromise DAA treatment efficacy remains an area of uncertainty. The discrepant results may arise from diverse patient characteristics and treatment regimens. The long-term survival benefit of HCV eradication in patients with active HCC remains to be studied. In this issue, the interaction between DAA and HCC will be reviewed.

Participants

1. Raymond T. Chung&Stephanie Marie Rutledge  Massachusetts General Hospital, Harvard Medical School, Boston, USA.
2. Suna Yapali  Division of Gastroenterology and Hepatology, Acibadem Mehmet Ali Aydinlar University, Turkey.
3. Tathagata Choudhuri  Visva-Bharati University, Santiniketan, India.
4. Ming Yang  Beijing Tsinghua Changgung Hospital, Beijing, China.
5. Mario Pirisi  Università del Piemonte Orientale, Novara, Italy.
6. Stefano Brillanti  Alma Mater Studiorum Università di Bologna, Bologna, Italy.
7. Tatsuo Kanda  Nihon University School of Medicine, Tokyo, Japan.
8. Mohamed Kohla  Menoufia University, Shebin El Kom, Egypt.
9. Sandra Ciesek  Institute of Medical Virology, University Hospital Frankfurt, Frankfurt, Germany.
10. Mohamed El Kassas  Helwan University, Cairo, Egypt.
11. Wen-Juei Jeng&Wei Teng  Chang Gung Memorial Hospital, Linkou branch, Taiwan.
12. Chia-Yen Dai  Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
13. Zahari A. Krastev  Sveti Ivan Rilski hospital, Sofia, Bulgaria.
14. Jung Hyun Kwon&Sun Hong Yoo  The Catholic University of Korea, Seoul, South Korea.
15. Juan Socorro Armendariz-Borunda, Christian Monroy&Laura Sanchez  Tecnologico de Monterrey, Monterrey, Mexico.
16. Erica Villa  Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
17. David E Bernstein&Tai-Ping Lee  Hofstra Northwell School of Medicine, Hempstead, USA.
The list is arranged in no particular order and being updated.

Submission Deadline

30 Nov 2019

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/hr
Submission Deadline: 30 Nov 2019
Contacts: Haidi Ding, Assistant Editor, editor_Haidi@hrjournal.net

Published Articles